RT Journal Article
T1 COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.
A1 Mazagatos, Clara
A1 Delgado-Sanz, Concepción
A1 Monge, Susana
A1 Pozo, Francisco
A1 Oliva, Jesús
A1 Sandonis, Virginia
A1 Gandarillas, Ana
A1 Quiñones-Rubio, Carmen
A1 Ruiz-Sopeña, Cristina
A1 Gallardo-García, Virtudes
A1 Basile, Luca
A1 Barranco-Boada, María Isabel
A1 Hidalgo-Pardo, Olga
A1 Vazquez-Cancela, Olalla
A1 García-Vázquez, Miriam
A1 Fernández-Sierra, Amelia
A1 Milagro-Beamonte, Ana
A1 Ordobás, María
A1 Martínez-Ochoa, Eva
A1 Fernández-Arribas, Socorro
A1 Lorusso, Nicola
A1 Martínez, Ana
A1 García-Fulgueiras, Ana
A1 Sastre-Palou, Bartolomé
A1 Losada-Castillo, Isabel
A1 Martínez-Cuenca, Silvia
A1 Rodríguez-Del Águila, Mar
A1 Latorre, Miriam
A1 Larrauri, Amparo
A1 SARI surveillance VE group in Spain, 
K1 COVID-19
K1 COVID-19 vaccine
K1 SARI surveillance
K1 SARS-CoV-2
K1 Spain
K1 test-negative design
K1 vaccine effectiveness
AB With the emergence of SARS-CoV-2, influenza surveillance systems in Spain were transformed into a new syndromic sentinel surveillance system. The Acute Respiratory Infection Surveillance System (SiVIRA in Spanish) is based on a sentinel network for acute respiratory infection (ARI) surveillance in primary care and a network of sentinel hospitals for severe ARI (SARI) surveillance in hospitals. Using a test-negative design and data from SARI admissions notified to SiVIRA between January 1 and October 3, 2021, we estimated COVID-19 vaccine effectiveness (VE) against hospitalization, by age group, vaccine type, time since vaccination, and SARS-CoV-2 variant. VE was 89% (95% CI: 83-93) against COVID-19 hospitalization overall in persons aged 20 years and older. VE was higher for mRNA vaccines, and lower for those aged 80 years and older, with a decrease in protection beyond 3 months of completing vaccination, and a further decrease after 5 months. We found no differences between periods with circulation of Alpha or Delta SARS-CoV-2 variants, although variant-specific VE was slightly higher against Alpha. The SiVIRA sentinel hospital surveillance network in Spain was able to describe clinical and epidemiological characteristics of SARI hospitalizations and provide estimates of COVID-19 VE in the population under surveillance. Our estimates add to evidence of high effectiveness of mRNA vaccines against severe COVID-19 and waning of protection with time since vaccination in those aged 80 or older. No substantial differences were observed between SARS-CoV-2 variants (Alpha vs. Delta).
YR 2022
FD 2022-07-26
LK http://hdl.handle.net/10668/19976
UL http://hdl.handle.net/10668/19976
LA en
DS RISalud
RD Apr 10, 2025